©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Interplay of Sp1 and Egr-1 in the Proximal Platelet-derived Growth Factor A-Chain Promoter in Cultured Vascular Endothelial Cells (*)

(Received for publication, June 28, 1995)

Levon M. Khachigian (§) Amy J. Williams Tucker Collins (¶)

From the Vascular Research Division, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The platelet-derived growth factor (PDGF) A-chain has been implicated in the initiation and progression of vascular occlusive lesions. The elements in the human PDGF-A promoter that mediate increased expression of the gene in vascular endothelial cells have not been identified. A potent inducer of PDGF-A expression in endothelial cells is phorbol 12-myristate 13-acetate (PMA). 5`-Deletion and transfection analysis revealed that a G+C-rich region in the proximal PDGF-A promoter is required for PMA-inducible gene expression. This region bears overlapping consensus recognition sequences for Sp1 and Egr-1. PMA induces Egr-1 mRNA expression within 1 h, whereas PDGF-A transcript levels increase after 2-4 h. Constitutive levels of Sp1 are not altered over 24 h. A specific nucleoprotein complex is formed when an oligonucleotide bearing the G+C-rich element is incubated with nuclear extracts from PMA-treated cells. The temporal appearance of this complex is consistent with the transient increase in Egr-1 transcripts. Antibodies to Egr-1 completely supershift the PMA-induced complex. Interestingly, increased nuclear levels of Egr-1 attenuate the ability of Sp1 to interact with the oligonucleotide, implicating competition between Egr-1 and Sp1 for the G+C-rich element. Binding studies with recombinant proteins demonstrate that Egr-1 can displace Sp1 from this region. Insertion of the G+C-rich element into a hybrid promoter-reporter construct confers PMA inducibility on the construct. Mutations that abolish Egr-1 binding also abrogate expression induced by PMA or overexpressed Egr-1. These findings demonstrate that PMA-induced Egr-1 displaces Sp1 from the G+C-rich element and activates expression driven by the PDGF-A proximal promoter in endothelial cells. The Sp1/Egr-1 displacement mechanism may be an important regulatory circuit in the control of inducible gene expression in vascular endothelial cells.


INTRODUCTION

The platelet-derived growth factor (PDGF) (^1)is a potent mitogen that has been implicated to play a role in a diversity of normal and pathological settings (for reviews see Heldin(1992), Khachigian and Chesterman(1993), and Ross(1993)). PDGF occurs as a homodimer or heterodimer of A- and B-chains covalently linked by disulfide bonds and has a relative molecular mass of approximately 28 kDa. The biological response to PDGF is mediated by high affinity cell-surface receptors with split tyrosine kinase domains. The alpha-receptor is bound by both polypeptide chains of PDGF, whereas the beta-subunit is bound with high affinity only by the B-chain (Heldin et al., 1988). PDGF A-chain mRNA has been detected in a variety of cells of human origin in culture (Betsholtz et al., 1986; Raines et al., 1990) and undergoes alternative splicing of exons 2 (Sanchez et al., 1991) and 6 (Collins et al., 1987; Tong et al., 1987). Three transcript species can be generated from the human PDGF-A gene (Bonthron et al., 1988), which are derived from the same transcriptional start site (Takimoto et al., 1991) and arise from the utilization of alternative poly(A) sites in exon 7 (Bonthron et al., 1988). Somatic cell hybrid chromosome segregation analysis (Betsholtz et al., 1986) and in situ hybridization using endothelial cell-derived cDNA (Bonthron et al., 1988) or non-isotopic techniques and genomic clones (Bonthron et al., 1992) assigned the gene to chromosome 7 (7p21-p22).

Isolation of genomic clones encoding the human PDGF A-chain gene allowed characterization of its structural organization and facilitated subsequent investigation of the molecular mechanisms controlling transcription of the gene (Bonthron et al., 1988; Rorsman et al., 1988; Takimoto et al., 1991). The human PDGF A-chain gene spans approximately 24 kilobases of genomic DNA and has a single transcriptional start site located 36 bp downstream of the TATA box (Bonthron et al., 1988). The minimal promoter region, sufficient for optimal promoter activity, consists of approximately 150 bp in human epithelial carcinoma (HeLa) cells (Lin et al., 1992) and 120 bp in African green monkey renal epithelial (BSC-1) cells (Kaetzel et al., 1994). This region, rich in G+C content, is hypersensitive to cleavage by S1 nuclease (Wang et al., 1992a) and contains potential overlapping recognition elements for the zinc-finger transcription factor, Sp1 (Dynan and Tjian, 1983; Kadonaga et al., 1987), the immediate-early growth response gene product, Egr-1 (Krox-24, zif268) (Rauscher et al., 1990), and the Wilms' tumor suppressor gene product, WT-1 (Rauscher et al., 1990). Although this G+C-rich sequence in the PDGF-A promoter is bound by nuclear proteins from cultured BSC-1 cells (Kaetzel et al., 1994), and Egr-1 and WT-1 overexpression can modulate promoter activity (Gashler et al., 1992; Wang et al., 1992b), it is unclear whether Sp1, Egr-1, or WT-1 actually play a physiologic role in the transcriptional regulation of PDGF-A. Several upstream promoter regions have also been implicated in the induced expression of the gene. First, a novel element located between bp -102 and -82 interacts with nuclear protein(s) (PDGF-A-BP-1) in human mesangial cells exposed to phorbol 12-myristate 13-acetate (PMA) (Bhandari et al., 1995). Second, a consensus serum response element between bp -477 and -468 mediates PDGF-induced reporter gene expression in human foreskin fibroblasts (Lin et al., 1992). The PDGF-A promoter is also subject to negative transcriptional regulation. Overexpression of WT-1 represses PDGF-A promoter-dependent reporter gene expression in murine fibroblasts and human embryonic kidney cells (Gashler et al., 1992; Wang et al., 1992b). Additionally, 5`-deletion analysis in BSC-1 cells defined two negative regulatory regions located between bp -1800 and -1029 and bp -1029 and -880 (Kaetzel et al., 1994). The identity of the endogenous nuclear transcription factors that actually interact with any of the regulatory regions in the PDGF-A promoter has not been determined.

In this report, PMA was used as a model agonist to define specific nuclear transcription factors that interact with functional nucleotide elements in the proximal PDGF-A promoter in cultured vascular endothelial cells. Using 5`-deletion and transient transfection analysis, we demonstrate the requirement for the region between bp -71 and -55 for PMA-inducible expression. This region bears overlapping Egr-1 and Sp1 binding elements. Northern blot analysis reveals that PMA induces Egr-1 expression with a time course earlier than PDGF-A, whereas Sp1 transcript levels are unchanged. Gel shift and supershift studies demonstrate that both PMA-induced and recombinant Egr-1 bind to the G+C-rich element by displacing Sp1. Mutations that abolish the ability of Egr-1 to interact with the proximal PDGF-A promoter also abrogate expression induced either by PMA or overexpressed Egr-1. Thus, PMA-induced expression of the PDGF A-chain in endothelial cells is mediated, at least in part, by the rapid and transient induction of Egr-1 and involves an interchange of factors occupying the G+C-rich element in the proximal promoter. This displacement mechanism may be a common theme in the induced expression of the PDGF A-chain gene by multiple signals in a variety of biological settings.


EXPERIMENTAL PROCEDURES

Oligonucleotide Synthesis, Purification, and Radiolabeling

Oligonucleotides were synthesized using a 392 DNA synthesizer (Applied Biosystems) and purified by gel electrophoresis. Oligonucleotides were end labeled with [-P]ATP (DuPont NEN) using T4 polynucleotide kinase (New England Biolabs) and purified using Chromaspin-10 columns (Clontech).

Plasmid Construction

A nested series of 5`-deletion fragments of the human PDGF A-chain promoter that were fused to chloramphenicol acetyltransferase (CAT) cDNA (Gashler et al., 1992; Kaetzel et al., 1994) was used in transient transfection assays in BAEC. Constructs A.SV40-CAT and Am.SV40-CAT were built by blunt-end subcloning the appropriate double-stranded oligonucleotide into the BglII site of pCAT promoter (Promega). Introduced sequences were confirmed by nucleotide sequencing using the dideoxynucleotide termination method with modified T7 polymerase (U. S. Biochemical Corp.) and [alpha-S]dATP (DuPont NEN).

Cell Culture

BAEC were grown in Dulbecco's modified Eagle's medium (Life Technologies, Inc.), pH 7.4, containing 10% calf serum. Cells were passaged every 3-4 days in 75-cm^2 flasks (Corning) by a rinse twice with phosphate-buffered saline, pH 7.4, and incubation with 0.05% trypsin, 0.02% EDTA in Hank's balanced salts solution (BioWhittaker) for 3 min at 37 °C prior to resuspension in growth medium. The media contained 50 µg/ml streptomycin and 50 IU/ml penicillin, and cultures were maintained at 37 °C in a humidified atmosphere of 5% CO(2)/air.

Transient Transfection and Assay for CAT Activity

Transfections in BAEC were carried out in 100-mm Petri dishes using 10 µg of plasmid construct and the modified calcium phosphate precipitation protocol (Sambrook et al., 1989). The cells were cotransfected with 2 µg of pTKGH (Nichols Institute Diagnostics) to correct for transfection efficiency. After incubation overnight at 37 °C and 3% CO(2)/air, the monolayers were washed twice with Hank's balanced salts solution and incubated with or without PMA (Sigma) for a further 24 h at 5% CO(2)/air. Prior to harvest, the conditioned media were sampled for human growth hormone by radioimmunoassay (Nichols Institute Diagnostics). CAT activity in the cell lysates was assessed by the two-phase fluor-diffusion technique (Sambrook et al., 1989).

Preparation of Nuclear Extracts

BAEC monolayers were washed twice with phosphate-buffered saline at 4 °C and removed from plates by scraping with a rubber policeman. The cells were centrifuged at 1200 rpm for 10 min at 4 °C, resuspended in cold phosphate-buffered saline, and transferred to Eppendorf tubes. The suspension was repelleted using a microfuge at 6500 rpm for 20 s at 4 °C. The cells were lysed by incubation in buffer A (10 mM HEPES, pH 8, 1.5 mM MgCl(2), 10 mM KCl, 0.5 mM dithiothreitol (DTT), 200 mM sucrose, 0.5% Nonidet P-40, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 1 µg/ml leupeptin, 1 µg/ml aprotinin) for 5 min at 4 °C. The suspension was recentrifuged, and the crude nuclei were washed with buffer A prior to lysis in buffer C (20 mM HEPES, pH 8, 1.5 mM MgCl(2), 420 mM NaCl, 0.2 mM EDTA, 1 mM DTT, 0.5 mM PMSF, 1 µg/ml leupeptin, 1 µg/ml aprotinin). The nuclear extract was clarified by centrifugation, and the supernatant was combined 1:1 with buffer D (20 mM HEPES, pH 8, 100 mM KCl, 0.2 mM EDTA, 20% glycerol, 1 mM DTT, 0.5 mM PMSF, 1 µg/ml leupeptin, 1 µg/ml aprotinin). Extracts were immediately frozen on dry ice and stored at -80 °C until use.

Recombinant Proteins

Recombinant Sp1, purified from HeLa cells infected with recombinant vaccinia virus containing human Sp1 cDNA, was obtained from Promega and stored in 12 mM HEPES-KOH, pH 7.5, 50 mM KCl, 6 mM MgCl(2), 5 µM ZnSO(4), 0.05% Nonidet P-40, 1 mM DTT, and 50% glycerol. Recombinant Egr-1 (zinc-finger region) in 25 mM HEPES-KOH, pH 7.5, 100 mM KCl, 10 µM ZnSO(4), 0.1% Nonidet P-40, 1 mM DTT, and 5% glycerol (Rauscher et al., 1990) was generously provided by Dr F. J. Rauscher, III (Wistar Institute, PA).

Electrophoretic Mobility Shift Assay (EMSA)

Binding reactions involving nuclear extracts were carried out in a total volume of 20 µl containing 2 µl of extract, 1 µg of poly(dIbulletdC)-poly(dIbulletdC) (Sigma), 1 µg of salmon sperm DNA (Sigma), 5% sucrose, and P-labeled oligonucleotide probe (50,000-100,000 cpm) in 10 mM Tris-HCl, pH 8, 50 mM MgCl(2), 1 mM EDTA, 1 mM DTT, 5% glycerol, and 1 mM PMSF. The reaction was allowed to continue for 30 min at 22 °C. In supershift studies, 1 µl of the appropriate affinity-purified rabbit anti-peptide antibody (Santa Cruz) was incubated with the binding mixture for 10 min at 22 °C prior to the addition of the probe. Binding reactions involving recombinant proteins were carried out in a total volume of 20 µl containing 10 mM Tris-HCl, pH 8, 50 mM NaCl, 1 mM EDTA, 5% glycerol, 2 mM DTT, 0.5% Nonidet P-40, 1 mg/ml bovine serum albumin, and P-labeled oligonucleotide probe (50,000-100,000 cpm). Bound complexes were separated from the free probe by non-denaturing polyacrylamide gel electrophoresis using 1 times TBE running buffer. The gels were run at 200 V (constant voltage) for approximately 2 h and then dried under vacuum and autoradiographed overnight using Kodak X-OMAT-AR film.

In Vitro DNase I Footprint Analysis

A single end-labeled fragment spanning the proximal PDGF-A promoter was prepared by digesting construct pPACCATDeltaXho with Eco47III and HindIII, dephosphorylating the ends with calf intestinal alkaline phosphatase (New England Biolabs) and isolating the 135-bp fragment by electrophoresis on a 2% agarose gel and Qiagen bead purification. The fragment was P-labeled at both ends with T4 polynucleotide kinase and purified using spin columns. Following digestion with NaeI, the 112-bp fragment was purified using a 3% agarose gel and beads. The probe was designated [P]-A. Guanine ladders were generated by methylation of the probe with dimethyl sulfate (Aldrich) and subsequent piperidine (Sigma) cleavage.

Binding reactions using [P]-A were carried out in a total volume of 20 µl containing 2 µg of poly(dIbulletdC)-poly(dIbulletdC) (Sigma), 0.5% sucrose in 10 mM Tris-HCl, pH 8, 50 mM MgCl(2), 1 mM EDTA, 1 mM DTT, 5% glycerol, 20 µg of bovine serum albumin, and 1 mM PMSF and increasing amounts of recombinant protein. Following an incubation for 1 h at 4 °C, 20 µl of DNase buffer (25 mM NaCl, 10 mM HEPES, pH 7.9, 5 mM MgCl(2), 1 mM CaCl(2)) containing 0.02 units of DNase I (Promega) was added and allowed to digest for 5 min at this temperature. 10 µl of stop solution (150 mM EDTA, 5% SDS, 250 µg/ml salmon sperm DNA) was added to each tube, and phenol/chloroform was extracted prior to DNA precipitation with absolute ethanol. The pellets were washed with 70% ethanol, evaporated to dryness, and resuspended in sequencing sample buffer. The samples were boiled for 2 min and applied to an 8% sequencing gel and run at 1500 V. The gels were dried and autoradiographed overnight at -80 °C.

Total RNA Preparation and Northern Blot Analysis

Total RNA was prepared using TRIzol® reagent in accordance with the manufacturer's instructions (Life Technologies, Inc.). RNA samples (15 µg) were separated on 1% formaldehyde/agarose gels, transferred to a Hybond nylon membrane (Amersham), then hybridized with cDNA that had been labeled with [alphaP]dCTP (DuPont NEN). The blot was washed with 0.5 times SSC at 65 °C and exposed at -80 °C.


RESULTS

PMA Induces the Transient Expression of PDGF-A in Vascular Endothelial Cells

To determine the temporal pattern with which the PDGF-A gene is expressed in endothelial cells exposed to PMA, bovine aortic endothelial cells were incubated with 100 ng/ml PMA for various times, and steady-state mRNA levels were assessed by Northern blot analysis. The major 2.8-kilobase PDGF A-chain transcript was virtually undetectable in untreated cells (Fig. 1). However, significant hybridization was detected following 2-4 h of exposure to PMA. PDGF A-chain transcript levels remained elevated for 16 h before returning to control levels by 24 h (Fig. 1).


Figure 1: Northern blot analysis of vascular endothelial cells exposed to PMA. RNA was isolated either from unstimulated BAEC or cells that were incubated with 100 ng/ml PMA in normal growth medium for 0, 1, 2, 4, 6, 9, 12, 16, 20, or 24 h at 37 °C. Samples were normalized for total RNA (15 µg) prior to electrophoresis and transfer to a nylon membrane. The blots were hybridized with specific P-labeled cDNA probes, and binding was assessed by autoradiography as described under ``Experimental Procedures.''



Identification of Regions in the PDGF-A Promoter Required for Optimal Basal Activity and PMA-induced Gene Expression in Endothelial Cells

To define the minimal promoter region that mediates basal expression in cultured endothelial cells, BAEC were transiently transfected with reporter constructs bearing nested 5`-deletions of the PDGF-A promoter fused to CAT cDNA. Cells that were transfected with constructs pACCATDeltaXho, e33, and f28 (bearing 262, 110, and 71 bp of promoter sequence relative to the transcriptional start site, respectively) expressed significant levels of the reporter (Fig. 2), whereas construct f36 (-55 bp) was inactive (Fig. 2). Maximum reporter activity was obtained using construct e33 (Fig. 2). These data indicate that the minimal PDGF-A promoter region required for optimal gene expression in cultured endothelial cells consists of approximately 110 bp.


Figure 2: Effect of PMA on reporter gene expression driven by 5`-deletions of the human PDGF A-promoter. BAEC were transiently transfected with 15 µg of each construct and 2 µg of normalizing plasmid (pTKGH) using the calcium phosphate precipitation technique. The cells were incubated with 100 ng/ml PMA for 24 h at 37 °C. CAT activity (arbitrary units) was normalized to levels of human growth hormone in the supernatant as described under ``Experimental Procedures.''



PMA-induced CAT activity was detected in cells that were transfected with constructs pACCATDeltaXho, e33, and f28 (Fig. 2). Construct f36, however, was unable to mediate PMA-inducible gene expression (Fig. 2). The sequence between the 5`-deletion end points of f28 and f36 corresponds to a G+C-rich element that contains overlapping consensus nucleotide recognition sequences for the zinc-finger transcription factors Sp1 and Egr-1 (Fig. 3A). Cotransfection studies indicate that constructs e33 and f28 respond to overexpressed Sp1 and Egr-1, whereas f36 does not. (^2)Thus, basal and PMA-induced expression mediated by the PDGF-A promoter in endothelial cells requires the proximal G+C-rich element and may involve the participation of Sp1 and/or Egr-1. The relative increase in reporter activity in response to PMA is consistent with -fold increases in CAT activity reported elsewhere (Angel et al., 1988; Fazio et al., 1991; John et al., 1995).


Figure 3: Interaction of the G+C-rich element in the proximal PDGF-A promoter with nuclear proteins from endothelial cells exposed to PMA. A, oligonucleotide A bearing the nucleotide sequence between bp -76 and -47 in the human PDGF-A promoter. The putative Sp1 and Egr-1 binding sites are indicated. B, specific interaction of endothelial nuclear proteins with the A-chain promoter. EMSA was performed using P-oligonucleotide A and nuclear extracts from unstimulated BAEC or cells exposed to 100 ng/ml PMA for 1 h at 37 °C. C, time course appearance of complex A3. EMSA was performed using P-oligonucleotide A and nuclear extracts from cells exposed to 100 ng/ml PMA for 0, 1, 2, 4, 9, 12, and 24 h at 37 °C. D, supershift analysis using nuclear extracts of cells exposed to 100 ng/ml PMA for 1 h. The binding reaction contained 1 µl of the antibody indicated. Complexes A1-A5 are indicated by arrows. Binding and electrophoresis were carried out as described under ``Experimental Procedures.''



PMA Rapidly Induces Egr-1 Expression, but Not Sp1, in Vascular Endothelial Cells

PMA has been reported to induce the expression of Egr-1 in a variety of cell types (Esposito et al., 1994; Kanazashi et al., 1994; Larsen et al., 1994). However, the expression of Egr-1 by endothelial cells has not yet been reported. Northern blot analysis was performed to determine whether PMA could modulate the expression of Egr-1 and/or Sp1. PMA dramatically induced steady-state Egr-1 transcript levels in BAEC within 1 h of exposure (Fig. 1). Egr-1 mRNA levels remained elevated for 16 h and returned to control levels by 24 h (Fig. 1). In contrast, Sp1 is constitutively expressed and unaffected by exposure to PMA over 24 h (Fig. 1). These findings indicate that the induction of Egr-1 transcript expression by PMA precedes that of the PDGF A-chain. Western blot analysis revealed that PMA also increased PDGF A-chain and Egr-1 expression at the level of protein, whereas constitutive levels of Sp1 were unaffected.^2

An Oligonucleotide Bearing the G+C-rich Sequence in the Proximal PDGF-A Promoter Interacts with Endothelial Nuclear Proteins

To determine whether PMA could induce an interaction between proteins from endothelial nuclei and the proximal PDGF-A promoter, EMSA was performed using a P-labeled double-stranded oligonucleotide bearing the G+C-rich sequence (Oligo A, Fig. 3A). Using nuclear extracts from unstimulated BAEC, two prominent nucleoprotein complexes (A1 and A5) and two minor complexes with variable intensity (A2 and A4) were formed. All of these complexes were specifically competed by the presence of 50-100-fold molar excess of the unlabeled cognate in the binding reaction (Fig. 3B). The intensity of A5 suggests that the proteins involved in this complex are present in relatively large amounts in endothelial nuclei. An oligonucleotide bearing a consensus site for the ETS-class transcription factor, PEA-3, did not compete with these complexes at 100-fold molar excess.^2

Interaction of Egr-1 with the G+C-rich Element in the Proximal PDGF-A Promoter in Endothelial Cells Exposed to PMA

A single PMA-induced nucleoprotein complex was observed when P-oligonucleotide A was incubated with nuclear extracts from BAEC exposed to 100 ng/ml of PMA for 1 h (A3, Fig. 3B). Complex A3 was specifically competed by 50-fold molar excess of the oligonucleotide (Fig. 3B). Complexes A1, A2, A4, and A5 were unaffected by the presence of PMA (Fig. 3B). To determine the temporal pattern of PMA-induced DNA binding activity, P-oligonucleotide A was incubated with nuclear extracts from endothelial cells exposed to PMA for various times. The dramatic induction of complex A3 was sustained over 4 h, and levels remained elevated after 12 h before returning to control levels by 24 h (Fig. 3C). Interestingly, the time course with which complex A3 appears is remarkably similar to the pattern of Egr-1 mRNA expression induced by PMA (Fig. 1).

Polyclonal antipeptide antibodies were used to determine the identity of the nuclear protein(s) involved in the PMA-induced complex. A complete supershift of complex A3 was obtained using antibodies directed toward Egr-1 (Fig. 3D). Thus, Egr-1 interacts with the PDGF-A G+C-rich element in cultured endothelial cells within 1 h of exposure to PMA. AP-2 and WT-1 are zinc-finger transcription factors that interact with the G+C-rich nucleotide sequences, 5`-(C/T)(C/G)(C/G)CC(C/A)N(G/C)(G/C)(G/C)-3` (Imagawa et al., 1987; Williams et al., 1989) and 5`-GCGTGGGAGT-3` (Nakagama et al., 1995), respectively. Antibodies to AP-2, WT-1, or to PEA-3, however, failed to produce a supershift (Fig. 3D).

Displacement of Sp1 by Egr-1 in Endothelial Cells Exposed to PMA

The constitutive expression of Sp1 in endothelial cells (Fig. 1) suggests that this transcription factor occupies the G+C-rich element in the absence of PMA. Supershift analysis was used to determine whether nuclear Sp1 does indeed occupy this element in cultured BAEC. In unstimulated cells, polyclonal antipeptide antibodies directed toward Sp1 partially supershifted complex A1 (Fig. 4). Upon exposure to PMA, however, Egr-1 bound to the promoter fragment, and the Sp1 supershift was no longer apparent (Fig. 4). Antibodies to Ets-1 or Ets-2 had no effect (Fig. 4). These data indicate that PMA can affect the nature of the transcription factors interacting with this region of the promoter. Egr-1 interacts with the G+C-rich element in the PDGF-A promoter by displacing Sp1 in endothelial cells exposed to PMA. The inability of the Sp1 antibody to completely supershift complex A1 may be due to one or a combination of several possibilities: first, partial recognition of bovine Sp1 using the anti-human Sp1 antibody; second, comigration of a nucleoprotein complex unrelated to Sp1; and third, incomplete recognition due to the phosphorylation state of Sp1 (reviewed in Imagawa et al. (1987)). Partial supershifts involving the same Sp1 antibody used in this study have been reported elsewhere (Kramer et al., 1994; Minowa et al., 1994; Jensen et al., 1995).


Figure 4: Induction of Egr-1 by PMA attenuates the ability of Sp1 to interact with the A-chain promoter oligonucleotide. EMSA was performed using P-oligonucleotide A and nuclear extracts from BAEC exposed to 100 ng/ml PMA for 1 h at 37 °C. Complexes A1-A5 are indicated by the arrows. S denotes a supershift and is indicated by the arrow. Nuclear extracts were corrected for protein concentration prior to assay. Binding and electrophoresis were carried out as described under ``Experimental Procedures.''



Recombinant Sp1 and Egr-1 Interact with the G+C-rich Element in the Proximal PDGF-A Promoter in a Dose-dependent and Stable Manner

Recombinant proteins were used to further document the interaction of Sp1 and Egr-1 with the G+C-rich element in the proximal PDGF-A promoter. Both Sp1 (Fig. 5A) and Egr-1 (Fig. 5B) bound to P-oligonucleotide A in a dose-dependent and specific manner. The appearance of higher order complexes at higher concentrations of Sp1 or Egr-1 (Fig. 5, A and B) indicates that more than one molecule, either Sp1 or Egr-1, may bind simultaneously to the oligonucleotide. Inspection of the nucleotide sequence in oligonucleotide A (Fig. 3A) indicates the presence of more than one putative binding site for each protein. Higher order complexes could also result from direct protein-protein interactions (Pascal and Tjian, 1991). In vitro DNase I footprinting provided further evidence for the interaction of Egr-1 with the G+C-rich element in the proximal PDGF-A promoter. Egr-1 protected this region from partial digestion in a dose-dependent manner (Fig. 5C). Sequences protected by Egr-1 beyond the actual binding site (Rauscher et al., 1990) may reflect weak binding of Egr-1 to adjacent G+C-rich sequences or conformational changes induced by bound Egr-1.


Figure 5: Interaction of recombinant Sp1 and Egr-1 with the proximal A-chain promoter. EMSA using Sp1 (A) or Egr-1 (B) in a binding reaction with P-oligonucleotide A. C, in vitro DNase I footprinting using Egr-1 with the single end-labeled PDGF-A probe ([P]-A). [P]-A was incubated with increasing amounts of recombinant Egr-1 for 60 min at 4 °C. DNase I (0.02 units) was added to the binding reaction and incubated for 5 min at this temperature. Electrophoresis was carried out as described under ``Experimental Procedures.'' Temporal stability of nucleoprotein complexes involving Sp1 (D) and Egr-1 (E). Bound complexes and free probe are indicated by arrows. Recombinant proteins were incubated with P-oligonucleotide A for 30 min at 22 °C and incubated with a 1000-fold molar excess of unlabeled oligonucleotide A for the periods indicated. The binding mixture was applied to a running non-denaturing polyacrylamide gel at the times indicated. Electrophoresis was carried out as described under ``Experimental Procedures.''



To provide an indication of the stability of the nucleoprotein complexes involving Sp1 and Egr-1 over time, EMSA was carried out using the running gel technique (Franzoso et al., 1993). Recombinant Sp1 was incubated with P-oligonucleotide A for 30 min at 22 °C and applied to a non-denaturing polyacrylamide gel following various times. The Sp1-P-oligonucleotide A complex was apparent even after 150 min at this temperature (Fig. 5D). Addition of 1000-fold molar excess of unlabeled oligonucleotide A displaced Sp1 from P-oligonucleotide A within 30 min (Fig. 5D). When recombinant Egr-1 was used instead of Sp1, the nucleoprotein complex was similarly apparent after 150 min (Fig. 5E). Unlike Sp1, however, addition of excess unlabeled oligonucleotide A resulted only in partial displacement of the prebound Egr-1 (Fig. 5E). These results indicate that both Sp1 and Egr-1 bind to the PDGF-A oligonucleotide in a stable manner. The apparent off-rate of Egr-1, however, is slower than that of Sp1.

Displacement of Prebound Recombinant Sp1 by Egr-1

The preceding results indicate that PMA-induced Egr-1 interacts with the G+C-rich element in the PDGF-A core promoter and that levels of Sp1 were unaffected in endothelial cells exposed to PMA. We hypothesized that Egr-1, induced by PMA, could displace Sp1 from this element in the promoter. Using recombinant proteins and the running gel technique, the effect of adding a 40-fold molar excess of Egr-1 (relative to Sp1) to a solution containing prebound Sp1-P-oligonucleotide A was the displacement of Sp1 within 30 min (Fig. 6A). Moreover, when the P-labeled footprint probe was allowed to bind to a fixed amount of Sp1 for 10 min and was subsequently challenged with increasing concentrations of Egr-1, Sp1 was displaced in a dose-dependent manner (Fig. 6B). Thus, Egr-1 is able to displace Sp1 from the G+C-rich element in the proximal PDGF-A promoter.


Figure 6: Interplay of recombinant Sp1 and Egr-1 at the proximal PDGF-A promoter. A, displacement of prebound Sp1 by Egr-1 using P-oligonucleotide A and running EMSA. Recombinant Sp1 was incubated with P-oligonucleotide A for 30 min at 22 °C. A 40-fold molar excess of Egr-1 was added, and the mixture was applied to a non-denaturing polyacrylamide gel at the times indicated. Bound complexes and free probe are indicated by arrows. B, displacement of prebound Sp1 with Egr-1 using the P-labeled footprint probe ([P]-A) in EMSA. [P]-A was incubated with a fixed amount of Sp1 or buffer alone for 10 min. Increasing amounts of recombinant Egr-1 were added and incubated for a further 20 min. Binding and electrophoresis were carried out as described under ``Experimental Procedures.''



Disruption of the G+C-rich Sequence Abrogates Egr-1 Binding and Abolishes Expression Inducible by PMA or Overexpressed Egr-1

To determine whether the interaction of Egr-1 with the G+C-rich element is necessary for inducible expression driven by the PDGF-A promoter, the oligonucleotide was mutated by the insertion of 3 guanines into the core sequence. When the mutant oligonucleotide, Oligo Am, was P-radiolabeled and used in EMSA, Egr-1 could no longer interact with the promoter sequence (Fig. 7A). Native and mutant A-chain promoter sequences were introduced into a heterologous promoter-reporter construct and transiently transfected into BAEC. Cells transfected with the wild-type construct expressed 5-6-fold greater CAT activity when exposed to PMA for 24 h (Fig. 7B). In contrast, CAT activity did not increase in cells transfected with the mutant construct (Fig. 7B). Similarly, expression driven by the wild-type sequence increased by 5-fold when BAEC were cotransfected with CMV.Egr-1 (Fig. 7C). However, the mutant failed to respond to overexpressed Egr-1 (Fig. 7C). These findings demonstrate the requirement of an intact Egr-1 site in the proximal PDGF-A promoter sequence for expression inducible either by PMA or overexpressed Egr-1.


Figure 7: Mutation of the Egr-1 binding site in the proximal PDGF-A promoter abolishes expression inducible by PMA or Egr-1. A, EMSA was performed using recombinant Egr-1 with either P-oligonucleotide A or its mutant ([P]-Oligo Am). BAEC were transiently transfected with 10 µg of SV40-based heterologous promoter CAT reporter constructs bearing either wild-type (A.SV40-CAT) or mutant (Am.SV40-CAT) PDGF-A promoter sequences. The cells were either incubated with 100 ng/ml PMA for 24 h at 37 °C (B) or cotransfected with the Egr-1 expression vector, CMV.Egr-1 (C). CAT activity (arbitrary units) was normalized to levels of human growth hormone in the supernatant as described under ``Experimental Procedures.''




DISCUSSION

The present report indicates that the induction of PDGF A-chain expression in endothelial cells by PMA involves the interplay of zinc-finger transcription factors with elements in the core promoter. A schematic representation of these events appears in Fig. 8. Several lines of evidence support this model. First, 5`-deletion analysis of the PDGF-A promoter indicates that Sp1 elements are required for basal expression in endothelial cells (Fig. 2), consistent with findings in other cell types (Kaetzel et al., 1994; Lin et al., 1992). The actual number of Sp1 sites required for basal activity is not clear. However, single point mutations in individual putative Sp1 sites did not reduce PDGF-A promoter activity, (^3)suggesting that not all Sp1 sites are required for basal expression. Second, recombinant Sp1 interacts with the G+C-rich element in a specific (Fig. 5A), dose-dependent (Fig. 5A) (Kim et al., 1989), and stable manner (Fig. 5D). Third, EMSA, using nuclear extracts from unstimulated cells, indicates that the G+C-rich element in the proximal PDGF-A promoter is occupied by Sp1 (Fig. 4). Finally, the constitutive expression of Sp1 transcript (Fig. 1) and protein^2 is not affected by PMA. Sp1, which was first identified in HeLa cells by virtue of its ability to activate the SV40 early promoter (Dynan and Tjian, 1983), mediates the basal expression of the structurally similar PDGF-B gene in cultured endothelial cells (Khachigian et al., 1994).


Figure 8: Model for the displacement of Sp1 by Egr-1 in endothelial cells exposed to PMA. Sp1 binds to the proximal PDGF-A promoter and mediates basal expression of the gene. Egr-1 induced by PMA displaces Sp1 from the G+C-rich element and stimulates PDGF-A gene expression. Although the actual molecular stoichiometry of Sp1 and Egr-1 occupying the proximal promoter is unclear, three Sp1 and two Egr-1 molecules are represented in the model based on the number of consensus elements in this region (Fig. 3A) and higher order binding (Fig. 5, A and B). The nuclear protein A5, which interacts with an undefined site in the proximal promoter, is not displaced by PMA-induced Egr-1 (Fig. 3B).



Upon exposure of endothelial cells to PMA, Egr-1 is induced and binds to the G+C-rich element in the proximal promoter by displacing Sp1. Several findings support this part of the model (Fig. 8). First, EMSA and in vitro DNase I footprinting studies indicate that like Sp1, recombinant Egr-1 interacts with the G+C-rich element in a specific (Fig. 5B), dose-dependent (Fig. 5, B and C), and stable (Fig. 5E) manner. The number of functional Egr-1 sites required for induced PDGF-A expression is not clear. Second, Egr-1 mRNA is dramatically induced in endothelial cells within minutes of exposure to PMA (Fig. 1). Third, the time course of induction of Egr-1 mRNA is virtually identical to appearance of the nucleoprotein complex A3 (Fig. 3C). Fourth, supershift analysis indicates that PMA-induced Egr-1 attenuates the ability of Sp1 to interact with the promoter (Fig. 4). Finally, a molar excess of Egr-1 can displace prebound Sp1 from this region (Fig. 6, A and B). It is unlikely that Egr-1 and Sp1 interact simultaneously with the G+C-rich element in the proximal PDGF-A promoter. The presence of both Egr-1 and Sp1 in the same EMSA reaction does not result in a super complex (Fig. 6, A and B), and antibodies to Egr-1 or Sp1 do not supershift a single band from endothelial cell nuclear extracts (Fig. 4). Collectively, these findings indicate that PMA-induced Egr-1 stimulates gene expression driven by the PDGF-A promoter in endothelial cells by displacement of Sp1 from the G+C-rich element.

The molecular mechanism(s) responsible for the return of PDGF-A transcript mRNA to basal levels following induction by PMA are unclear. It is tempting to speculate, however, that one or more of the following transcriptional events may be involved. First, the transient increase in Egr-1 transcript (Fig. 1), protein,^2 and DNA binding activity (Fig. 3B) suggests that Sp1 may reoccupy the G+C-rich element when the stoichiometric ratio of Sp1 to Egr-1 returns to preinduction levels, greatly favoring Sp1. Second, Egr-1 could be actively displaced by a third transcription factor such as WT-1. Recombinant WT-1 has been shown previously to interact with the same G+C-rich element in the proximal PDGF-A promoter (Gashler et al., 1992; Wang et al., 1992b). We did not detect a nucleoprotein complex involving endothelial WT-1 by supershift analysis; however, a WT-1-like transcription factor may be involved in the post-induction transcriptional repression of PDGF-A. Finally, other regulatory proteins could displace Egr-1 from the G+C-rich element via direct protein-protein interactions. For example, the activation of creatine kinase gene expression by WT-1 is repressed by physical association with p53 (Maheswaran et al., 1993). Interestingly, an active transcriptional repression mechanism has also been suggested in the down-regulation of PDGF-A gene expression after serum stimulation (Takimoto and Kuramoto, 1995).

The regulatory events presented in this manuscript indicate that the complex process of transcriptional activation can involve the interchange of transcription factors associating with distinct promoter elements (Tjian and Maniatis, 1994). Interestingly, overlapping putative nucleotide recognition elements for Egr-1 and Sp1 appear in the promoters of human tissue factor (Mackman et al., 1989), transforming growth factor-beta1 (Kim et al., 1989; Dey et al., 1994), colony-stimulating factor-1 (Harrington et al., 1993), tumor necrosis factor (Kramer et al., 1994), murine thrombospondin-1 (Shingu and Bornstein, 1994), acetylcholinesterase (Mutero et al., 1995), and in the Egr-1 promoter itself (Cao et al., 1993). Although binding and cotransfection studies have implied a functional role for Sp1 and Egr-1 in the regulation of certain of these genes, actual competition between these factors has not been demonstrated. Accordingly, the exchange of Sp1 and Egr-1 at overlapping motifs may be an important common event in the control of inducible gene expression.


FOOTNOTES

*
This work was supported in part by National Institutes of Health Grants HL 35716, HL 45462, PO1 36028, and T32 07627. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Supported by a C. J. Martin Postdoctoral Research Fellowship (National Health and Medical Research Council of Australia) and a J. William Fulbright Postdoctoral Research Fellowship.

Established Investigator of the American Heart Association. To whom correspondence should be addressed: Vascular Research Division, Dept. of Pathology, Brigham and Women's Hospital, 221 Longwood Ave., Boston, MA 02115. Tel.: 617-732-5990; Fax: 617-278-6990.

(^1)
The abbreviations used are: PDGF, platelet-derived growth factor; Egr-1, early growth response gene product; WT, Wilms' tumor; PMA, phorbol 12-myristate 13-acetate; CAT, chloramphenicol acetyltransferase; BAEC, bovine aortic endothelial cells; EMSA, electrophoretic mobility shift assay; bp, base pair(s); DTT, dithiothreitol; PMSF, phenylmethylsulfonyl fluoride.

(^2)
L. M. Khachigian, A. J. Williams, and T. Collins, unpublished observations.

(^3)
T. Collins and D. T. Bonthron, unpublished observations.


ACKNOWLEDGEMENTS

We thank Drs. David T. Bonthron (Human Genetics Unit, University of Edinburgh, Scotland) for generously providing certain PDGF-A promoter-reporter deletion constructs, Vikas P. Sukhatme (Beth Israel Hospital and Harvard Medical School, Boston) for CMV.Egr-1, and Frank J. Rauscher III (Wistar Institute of Anatomy and Biology, Philadelphia) for recombinant Egr-1.


REFERENCES

  1. Angel, P., Hattori, K., Smeal, T., and Karin, M. (1988) Cell 55, 875-885 [Medline] [Order article via Infotrieve]
  2. Betsholtz, C., Johnsson, A., Heldin, C.-H., Westermark, B., Lind, P., Urdea, M. S., Eddy, R., Shows, T. B., Philpott, K., Mellor, A. L., Knott, T. J., and Scott, J. (1986) Nature 320, 695-699 [Medline] [Order article via Infotrieve]
  3. Bhandari, B., Wenzel, U. O., Marra, F., and Abboud, H. E. (1995) J. Biol. Chem. 270, 5541-5548 [Abstract/Free Full Text]
  4. Bonthron, D. T., Morton, C. C., Orkin, S. H., and Collins, T. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 1492-1496 [Abstract]
  5. Bonthron, D., Collins, T., Grzeschik, K.-H., van Roy, N., and Spelman, F. (1992) Genomics 13, 257-263 [Medline] [Order article via Infotrieve]
  6. Cao, X., Mahendran, R., Guy, G. R., and Tan, Y. H. (1993) J. Biol. Chem. 268, 16949-16957 [Abstract/Free Full Text]
  7. Collins, T., Bonthron, D. T., and Orkin, S. H. (1987) Nature 328, 621-624 [Medline] [Order article via Infotrieve]
  8. Dey, B. R., Sukhatme, V. P., Roberts, A. B., Sporn, M. B., Rauscher, F. J., III, and Kim, S. J. (1994) Mol. Endocrinol. 8, 595-602 [Abstract]
  9. Dynan, W. S., and Tjian, R. (1983) Cell 35, 79-87 [Medline] [Order article via Infotrieve]
  10. Esposito, F., Agosti, V., Morrone, G., Morra, F., Cuomo, C., Russo, T., Venuta, S., and Cimino, F. (1994) Biochem. J. 301, 649-653 [Medline] [Order article via Infotrieve]
  11. Fazio, M. J., O'Leary, J., Kahari, V. M., Chen, Y. Q., Saitta, B., and Uitto, J. (1991) J. Invest. Dermatol. 97, 281-285 [Abstract]
  12. Franzoso, T., Bours, V., Azarenko, V., Park, S., Tomita-Yamaguchi, M., Kanno, T., Brown, K., and Siebenlist, U. (1993) EMBO J. 12, 3893-3901 [Abstract]
  13. Gashler, A. L., Bonthron, D. T., Madden, S. L., Rauscher, F. J., III, Collins, T., and Sukhatme, V. P. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10984-10988 [Abstract]
  14. Harrington, M. A., Konicek, B., Song, A., Xia, X., Fredericks, W. J., and Rauscher, F. J., III. (1993) J. Biol. Chem. 268, 21271-21275 [Abstract/Free Full Text]
  15. Heldin, C.-H. (1992) EMBO J. 11, 4251-4259 [Medline] [Order article via Infotrieve]
  16. Heldin, C.-H., Backstrom, G., Ostman, A., Hammacher, A., Ronnstrand, L., Rubin, K., Nister, M., and Westermark, B. (1988) EMBO J. 7, 1387-1393 [Abstract]
  17. Imagawa, M., Chiu, R., and Karin, M. (1987) Cell 51, 251-260 [Medline] [Order article via Infotrieve]
  18. Jensen, D. E., Rich, C. B., Terpstra, A. J., Farmer, S. R., and Foster, J. A. (1995) J. Biol. Chem. 270, 6555-6563 [Abstract/Free Full Text]
  19. John, S., Reeves, R. B., Lin, J.-X., Child, R., Leiden, J. M., Thompson, C. B., and Leonard, W. J. (1995) Mol. Cell. Biol. 15, 1786-1796 [Abstract]
  20. Kadonaga, J. T., Carner, K. R., Masiarz, F. R., and Tjian, R. (1987) Cell 51, 1079-1090 [Medline] [Order article via Infotrieve]
  21. Kaetzel, D. M., Maul, R. S., Liu, B., Bonthron, D. T., Fenstermaker, R. A., and Coyne, D. W. (1994) Biochem. J. 301, 321-327 [Medline] [Order article via Infotrieve]
  22. Kanazashi, S., Hata, D., Ishigami, T., Jung, E. Y., Shintaku, N., Sumimoto, S., Heike, T., Katamura, K., and Mayumi, M. (1994) Mol. Immunol. 31, 21-30 [Medline] [Order article via Infotrieve]
  23. Khachigian, L. M., and Chesterman, C. N. (1993) Platelets 4, 304-315
  24. Khachigian, L. M., Fries, J. W. U., Benz, M. W., Bonthron, D. T., and Collins, T. (1994) J. Biol. Chem. 269, 22647-22656 [Abstract/Free Full Text]
  25. Kim, S. J., Glick, A., Sporn, M. B., and Roberts, A. B. (1989) J. Biol. Chem. 264, 402-408 [Abstract/Free Full Text]
  26. Kramer, B., Meichle, A., Hensel, G., Charnay, P., and Kronke, M. (1994) Biochim. Biophys. Acta 1219, 413-421 [Medline] [Order article via Infotrieve]
  27. Larsen, F. G., Vorhees, J. J., and Astrom, A. (1994) J. Invest. Dermatol. 102, 730-733 [Abstract]
  28. Lin, X., Wang, Z.-Y., Gu, L., and Deuel, T. F. (1992) J. Biol. Chem. 267, 25614-25619 [Abstract/Free Full Text]
  29. Mackman, N., Morrissey, J. H., Fowler, B., and Edgington, T. S. (1989) Biochemistry 28, 1755-1762 [Medline] [Order article via Infotrieve]
  30. Maheswaran, S., Park, S., Bernard, A., Morris, J. F., Rauscher, F. J., III, Hill, D. E., and Haber, D. A. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 5100-5104 [Abstract]
  31. Minowa, T., Minowa, M. T., and Mouradian, M. M. (1994) J. Biol. Chem. 269, 11656-11662 [Abstract/Free Full Text]
  32. Mutero, A., Camp, S., and Taylor, P. (1995) J. Biol. Chem. 270, 1866-1872 [Abstract/Free Full Text]
  33. Nakagama, H. G., Heinrich, J., Pelletier, J., and Housman, D. (1995) Mol. Cell. Biol. 15, 1489-1498 [Abstract]
  34. Pascal, E., and Tjian, R. (1991) Genes & Dev. 5, 1646-1656
  35. Raines, R., Bowen-Pope, D. F., and Ross, R. (1990) in Handbook of Experimental Pharmacology (Sporn, M. B., and Roberts, A. B., eds) pp. 173-261, Springer-Verlag, Berlin
  36. Rauscher, F. J., III, Morris, J. F., Tournay, J. O. E., Cook, D. M., and Curran, T. (1990) Science 250, 1259-1262 [Medline] [Order article via Infotrieve]
  37. Rorsman, F., Bywater, M., Knott, T. J., Scott, J., and Betsholtz, C. (1988) Mol. Cell. Biol. 8, 571-577 [Medline] [Order article via Infotrieve]
  38. Ross, R. (1993) Nature 363, 801-809
  39. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
  40. Sanchez, A., Chesterman, C. N., and Sleigh, M. J. (1991) Gene (Amst.) 98, 295-298 [Medline] [Order article via Infotrieve]
  41. Shingu, T., and Bornstein, P. (1994) J. Biol. Chem. 269, 32551-32557 [Abstract/Free Full Text]
  42. Takimoto, Y., and Kuramoto, A. (1995) Biochim. Biophys. Acta 1260, 176-182 [Medline] [Order article via Infotrieve]
  43. Takimoto, Y., Wang, Z. Y., Kobler, K., and Deuel, T. F. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 1686-1690 [Abstract]
  44. Tjian, R., and Maniatis, T. (1994) Cell 77, 5-8 [Medline] [Order article via Infotrieve]
  45. Tong, B. D., Auer, D. E., Jaye, M., Kaplow, J. M., Ricca, G., McConathy, E., Drohan, W., and Deuel, T. F. (1987) Nature 328, 619-621 [Medline] [Order article via Infotrieve]
  46. Wang, Z., Lin, X.-H., Qui, Q. Q., and Deuel, T. F. (1992a) J. Biol. Chem. 267, 17022-17031 [Abstract/Free Full Text]
  47. Wang, Z.-Y., Madden, S. L., Deuel, T. F., and Rauscher, F. J., III (1992b) J. Biol. Chem. 267, 21999-22002 [Abstract/Free Full Text]
  48. Williams, T., Admon, A., Luscher, B., and Tjian, R. (1989) Genes & Dev. 3, 1507-1517

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.